Through the federal program BARDA-DRIVe, the Center for Biotechnology will receive financial resources to support the incubation of businesses that can innovate in the detection and treatment of sepsis. Sepsis is among the most expensive conditions treated in US hospitals, as well as a leading cause of hospital readmission, according to HHS.
“Stony Brook’s selection by the Department of Health & Human Services reflects our longstanding commitment to leadership and innovation in the fight against infectious disease,” said Stony Brook University President Samuel L. Stanley, Jr., MD. “Our stellar faculty is uniquely equipped to foster translational research in critical areas of health security.”
Stony Brook’s proposal is aimed at mining the robust academic portfolio of biomedical research within metropolitan New York, according to Clinton Rubin, SUNY Distinguished Professor in the Department of Biomedical Engineering in the College of Engineering and Applied Sciences.
“We are very excited that Stony Brook University’s Center for Biotechnology has been selected as one of eight HHS-BARDA-DRIVe accelerators, nationwide, each directed to support innovators to develop Health Security Innovations within our ‘ecosystem’,” Rubin said.
Stony Brook’s Center for Biotechnology develops bioscience innovations into next-generation biomedical products, facilitates new company formation and expansion, and supports the overall growth of the bioscience industry in New York State. The Center hosts the Long Island Bioscience Hub in collaboration with Cold Spring Harbor Laboratory, Brookhaven National Laboratory and the Feinstein Institute for Medical Research, with additional support provided by the National Institutes of Health REACH initiative (Research Evaluation and Commercialization Hub), Research Foundation for SUNY, and Empire State Development.